AIM: To study the distribution, metabolism and excretion of S-propargyl-cysteine (SPRC), a novel hydrogen sulfide (H2S) donor, after oral administration in rats. METHODS: Adult Sprague-Dawley rats were used. The tissue distribution of [(35)S] SPRC-derived radioactivity was measured using a liquid scintillation counter. The plasma protein binding of SPRC was examined using 96-well equilibrium dialysis. The excretion of SPRC in urine, bile and feces was analyzed using the LC-MS/MS method. The major metabolites in rat biomatrices were identified using MRM information-dependent, acquisition-enhanced product ion (MRM-IDA-EPI) scans on API 4000QTrap system. RESULTS: After oral administration of [(35)S]-SPRC at a dose of 75 mg/kg, [(35)S] SPRC-derived radioactivity displayed broad biological distribution in various tissues of rats, including its target organs (heart and brain) with the highest in kidney. On the other hand, the binding of SPRC to human, rat and dog plasma protein was low. Only 2.18% ± 0.61% and 0.77% ± 0.61% of the total SPRC administered was excreted unchanged in the bile and urine. However, neither intact SPRC nor its metabolites were detected in rat feces. The major metabolic pathway in vivo (rat bile, urine, and plasma) was N-acetylation. CONCLUSION: The preliminary results suggest that SPRC possesses acceptable pharmacokinetic properties in rats.
AIM: To study the distribution, metabolism and excretion of S-propargyl-cysteine (SPRC), a novel hydrogen sulfide (H2S) donor, after oral administration in rats. METHODS: Adult Sprague-Dawley rats were used. The tissue distribution of [(35)S] SPRC-derived radioactivity was measured using a liquid scintillation counter. The plasma protein binding of SPRC was examined using 96-well equilibrium dialysis. The excretion of SPRC in urine, bile and feces was analyzed using the LC-MS/MS method. The major metabolites in rat biomatrices were identified using MRM information-dependent, acquisition-enhanced product ion (MRM-IDA-EPI) scans on API 4000QTrap system. RESULTS: After oral administration of [(35)S]-SPRC at a dose of 75 mg/kg, [(35)S] SPRC-derived radioactivity displayed broad biological distribution in various tissues of rats, including its target organs (heart and brain) with the highest in kidney. On the other hand, the binding of SPRC to human, rat and dog plasma protein was low. Only 2.18% ± 0.61% and 0.77% ± 0.61% of the total SPRC administered was excreted unchanged in the bile and urine. However, neither intact SPRC nor its metabolites were detected in rat feces. The major metabolic pathway in vivo (rat bile, urine, and plasma) was N-acetylation. CONCLUSION: The preliminary results suggest that SPRC possesses acceptable pharmacokinetic properties in rats.
Authors: Yang Cao; Sharmila Adhikari; Abel Damien Ang; Philip K Moore; Madhav Bhatia Journal: Am J Physiol Cell Physiol Date: 2006-04-05 Impact factor: 4.249
Authors: Esperanza Garcia; Daniel Limon; Veronica Perez-De La Cruz; Magda Giordano; Mauricio Diaz-Muñoz; Perla D Maldonado; Maria Nieves Herrera-Mundo; Jose Pedraza-Chaverri; Abel Santamaria Journal: Free Radic Res Date: 2008-10
Authors: Hilde Laggner; Marcela Hermann; Harald Esterbauer; Markus K Muellner; Markus Exner; Bernhard Mk Gmeiner; Stylianos Kapiotis Journal: J Hypertens Date: 2007-10 Impact factor: 4.844
Authors: C Dello Russo; G Tringali; E Ragazzoni; N Maggiano; E Menini; M Vairano; P Preziosi; P Navarra Journal: J Neuroendocrinol Date: 2000-03 Impact factor: 3.627
Authors: Yicheng Mao; Yi Zhun Zhu; Ba Hieu Tran; Ying Yu; Lingling Chang; Bo Tan; Wanwan Jia; Ying Xiong; Tao Dai; Rui Zhong; Weiping Zhang; Van Minh Le; Peter Rose; Zhijun Wang Journal: Int J Nanomedicine Date: 2019-12-24